Expedient Synthesis of Quinazoline Analogues through Direct Nucleophilic Arylation/Alkylation of 2-Chloroquinazoline

Abstract

A practical approach was developed for the synthesis of 4-arylquinazoline compounds through a one-pot nucleophilic arylation/alkylation of 2-chloroquinazoline with aryl lithium compounds generated in situ, followed by ring oxidation. The obtained 2-chloro-4-arylquinazoline adducts were further used as versatile intermediates that undergo a variety of synthetic transformations to provide functionalized quinazoline compounds. The arylation intermediate dihydroquinazoline was also elaborated to the tricyclic dihydroimidazo[2,1-b]quinazolinone.

Keywords

arylation - heterocycles - quinazoline - nucleophilic addition - alkylation

• References

• 1 Vijaychand A, Manjula SN, Bharath EN, Divya B. Int. J. Pharma Bio Sci. 2011; 2: 780
• 2a Wang D, Gao F. Chem. Cent. J. 2013; 7: 97
• 2b Marzaro G, Guiotto A, Chilin A. Expert Opin. Ther. Pat. 2012; 22: 223
• 2c Ravez S, Castillo-Aguilera O, Depreux P, Goossens L. Expert Opin. Ther. Pat. 2015; 25: 789
• 3a Selvam TP, Kumar P, Vijayaraj P. Res. Pharm. 2011; 1: 1
• 3b Abida Parvez N, Rana A, Imran M. Int. J. Pharm. Bio. Arch. 2011; 2: 1651
• 3c For an early review, see: Johne S. Pharmazie 1981; 36: 583
• 4a Khan I, Ibrar A, Abbas N, Saeed A. Eur. J. Med. Chem. 2014; 76: 193 ; and references therein

For early reviews, see:
• 4b Johne S, Groger D. Pharmazie 1970; 25: 22
• 4c Coppola GM. Synthesis 1980; 505
• 4d Johne S. Prog. Drug Res. 1982; 26: 259
• 4e Johne S. Prog. Chem. Org. Nat. Prod. 1984; 46: 159
• 4f Michael JP. Nat. Prod. Rep. 2000; 17: 603
• 5a Wiesner J, Ortmann R, Jomaa H, Schlitzer M. Angew. Chem. Int. Ed. 2003; 42: 5274
• 5b Mital A. Curr. Med. Chem. 2007; 14: 759
• 5c Kumar V, Mahajan A, Chibale K. Bioorg. Med. Chem. 2009; 17: 2236
• 6a Amin AH, Mehta DR. Nature 1959; 183: 1317
• 6b Mehta DR, Naravane JS, Desai RM. J. Org. Chem. 1963; 28: 445
• 6c Jain MP, Koul SK, Dhar KL, Atal CK. Phytochemistry 1980; 19: 1880 ; and references cited therein
• 7a Duan J, Zhou R, Zhao S, Wang M, Che C. Zhongguo Yaoke Daxue Xuebao 1998; 29: 21
• 7b Fan Z, Yao X, Gu L, Wang J, Wang J, He A, Zhang B, Wang X, Wang H. Shenyang Yaoxueyuan Xuebao 1993; 10: 136
• 7c Rahman AU, Sultana N, Akhter F, Nighat F, Choudhary MI. Nat. Prod. Lett. 1997; 10: 249
• 7d Bhide MB, Mahajani SS. Bull. Haffkine Inst. 1975; 3: 128

For some examples, see:
• 8a Zhu S, Meng L, Zhang Q, Wei L. Bioorg. Med. Chem. Lett. 2006; 16: 1854
• 8b Bilbro J, Mart M, Kyprianou N. Anticancer Res. 2013; 33: 4695
• 8c Zhu S, Chandrashekar G, Meng L, Robinson K, Chatterji D. Bioorg. Med. Chem. 2012; 20: 927
• 9 Khan I, Ibrar A, Ahmed W, Saeed A. Eur. J. Med. Chem. 2015; 90: 124 ; and references therein
• 10a Andersson H, Almquist F, Olsson R. Org. Lett. 2007; 9: 1335
• 10b Bull JA, Mousseau JJ, Pelletier G, Charette AB. Chem. Rev. 2012; 112: 2642 ; and references therein
• 11a Bursavich MG, Lombardi S, Gilbert AM. Org. Lett. 2005; 7: 4113
• 11b Epifani E, Florio S, Ingrosso G. Tetrahedron Lett. 1987; 28: 6385
• 11c Harden DB, Mokrosz MJ, Strekowski L. J. Org. Chem. 1988; 53: 4137
• 12 Butters M, Ebbs J, Green SP, MacRae J, Morland MC, Murtiashaw CW, Petman AJ. Org. Process Res. Dev. 2001; 5: 28
• 13 A few reports on nucleophilic addition to quinazoline substrate can be found in the literature, see: Anderson C, Moreno J, Hadida S. Synlett 2014; 25: 677
• 14 Bursavich MG, Lombardi S, Gibert AM. Org. Lett. 2005; 7: 4113

For examples, see:
• 15a Chern J.-W, Tao P.-L, Wang K.-C, Gutcait A, Liu S.-W, Yen M.-H, Chien S.-L, Rong J.-K. J. Med. Chem. 1998; 41: 3128
• 15b Váradia A, Horvátha P, Kurtánb T, Mándib A, Tótha G, Gergelya A, Kökösia J. Tetrahedron 2012; 68: 10365

For marketed drug Quazinone:
• 15c Eigenmann R, Gerold M, Holck M. J. Cardiovasc. Pharmacol. 1984; 6: 511
• 15d Belz GG, Stern HC, Butzer R. J. Cardiovasc. Pharmacol. 1985; 7: 86
• 15e Holck M, Thorens S, Muggli R, Eigenmann R. J. Cardiovasc. Pharmacol. 1984; 6: 520